Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Imatinib Mesylate in Refractory Seminoma
NCT00042952Phase 2Terminated
- Sponsor
- National Cancer Institute
- Start
- Jun 2002
- Primary completion
- Oct 2003
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of imatinib in seminoma (testicular), Ovarian dysgerminoma, sponsored by National Cancer Institute. Started Jun 2002; status: terminated.
02
Drugs
03
Conditions
seminoma (testicular)Ovarian dysgerminoma
Beyond the preview
Go deeper on NCT00042952.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00042952.